Filament Health Corp. is a clinical-stage natural psychedelic drug development company, which engages in the discovery and development of natural psychedelic pharmaceuticals. The company is headquartered in Burnaby, British Columbia and currently employs 13 full-time employees. The Company’s platform of intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. The Company’s first three botanical drug candidates are standardized, purified extracts of Psilocybe cubensis fruiting bodies include: PEX010 Psilocybin - oral delivery (1mg and 25mg), PEX020 Psilocin - oral delivery (dose withheld), and PEX030 Psilocin - sublingual delivery (dose withheld). The firm's preclinical stage drug candidates include AEX010 Ayahuasca - oral delivery (dose withheld) and AEX020 Monoamine Oxidase Inhibitor - oral delivery (dose withheld). The Company’s internal drug discovery and development program is carried out by its wholly owned subsidiary, Psilo Scientific Ltd., and is focused on developing standardized pharmaceutical-grade drug candidates from botanical psychedelic biomass.
Mr. Benjamin Lightburn 2020 'den beri şirketle birlikte olan Filament Health Corp 'in Chairman of the Board 'ıdır.
Filament Health Corp. hissesinin fiyat performansı nasıl?
Filament Health Corp. 'in mevcut fiyatı $0.0001 'dir, son işlem günde 0% azalmış etti.
Filament Health Corp için ana iş temaları veya sektörler nelerdir?
Filament Health Corp N/A endüstrisine ait ve sektör N/A 'dir
Filament Health Corp 'in piyasa değerlemesi nedir?
Filament Health Corp 'in mevcut piyasa değerlemesi $26.1K 'dir
Filament Health Corp al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 3 analist Filament Health Corp için analist derecelendirmeleri gerçekleştirdi, bunlar 3 güçlü al, 5 al, 1 tut, 0 sat ve 3 güçlü sat içermektedir